|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...3334353637383940414243...156157» |
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Trial primary completion date, Combination therapy: An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 6, 2016
P=N/A, N=77, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2013
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) (clinicaltrials.gov) - Jul 5, 2016
P=N/A, N=227, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2013 Recruiting --> Active, not recruiting | N=300 --> 227
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion: ADJUVITE: Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jul 2, 2016
P2/3, N=34, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting | N=300 --> 227 Active, not recruiting --> Completed
- || Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Study to Observe the Safety and Efficacy of Etanercept (Enbrel (clinicaltrials.gov) - Jul 1, 2016
P=N/A, N=120, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Sep 2016
- Enrollment closed: Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diab (clinicaltrials.gov) - Jul 1, 2016
P2, N=36, Active, not recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Active, not recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed: Etaplus: Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jul 1, 2016
P=N/A, N=126, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- New trial: Impact of a Nutritional Intervention on Type1 Diabetes Adult With Metabolic Syndrome (clinicaltrials.gov) - Jul 1, 2016
P=N/A, N=28, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- Enrollment open: Closed-loop Control of Postprandial Glucose Levels After Meals With Different Macronutrients Content in Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2016
P2, N=15, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Enrollment open, Trial primary completion date: Accu-Chek (clinicaltrials.gov) - Jul 1, 2016
P=N/A, N=200, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Aug 2016
- ||| Enrollment open: ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT) (clinicaltrials.gov) - Jul 1, 2016
P=N/A, N=125, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- | Calquence (acalabrutinib) / AstraZeneca
Trial completion, Phase classification: ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate (clinicaltrials.gov) - Jun 30, 2016
P2a, N=31, Completed, Sponsor: Acerta Pharma BV
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Phase classification: P2 --> P2a
- New trial: The Effects of a Six-week Exercise Programme Undertaken by Women With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=24, Recruiting, Sponsor: Siobhan Graham
- | Trial completion: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 30, 2016
P1, N=48, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | Phase classification: P2 --> P2a Active, not recruiting --> Completed
- Enrollment change, Trial suspension, Biopsy: Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=96, Suspended, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed N=99999999 --> 96 | Recruiting --> Suspended
- Stelara (ustekinumab) / J&J
Trial primary completion date: Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis (clinicaltrials.gov) - Jun 29, 2016
P2, N=5, Recruiting, Sponsor: Jewish General Hospital
N=99999999 --> 96 | Recruiting --> Suspended Trial primary completion date: Sep 2016 --> Dec 2016
- Enrollment change, Trial suspension: Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=582, Suspended, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Sep 2016 --> Dec 2016 N=99999999 --> 582 | Recruiting --> Suspended
- New trial: Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=168, Not yet recruiting, Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- New trial, Patient reported outcomes: Patient Reported Outcomes Reported Via PC / Tablet Home Versus Touch Screen at Hospital Among Patients With Arthritis (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Henrik Gudbergsen
- || BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
Enrollment change, Trial primary completion date: A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog (clinicaltrials.gov) - Jun 29, 2016
P1, N=80, Recruiting, Sponsor: Adocia
N=99999999 --> 582 | Recruiting --> Suspended N=36 --> 80 | Trial primary completion date: Jan 2016 --> Oct 2016
- Phase classification, IO biomarker: Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=314, Completed, Sponsor: Carmel Medical Center
N=36 --> 80 | Trial primary completion date: Jan 2016 --> Oct 2016 Phase classification: P1 --> P=N/A
- New trial: Enhance Wellness for Individuals With Long-Term Physical Disabilities (clinicaltrials.gov) - Jun 28, 2016
P=N/A, N=240, Recruiting, Sponsor: University of Washington
- ||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Enrollment closed: Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe (clinicaltrials.gov) - Jun 28, 2016
P2, N=70, Active, not recruiting, Sponsor: Boehringer Ingelheim
Phase classification: P1 --> P=N/A Recruiting --> Active, not recruiting
- New trial: MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment. (clinicaltrials.gov) - Jun 27, 2016
P=N/A, N=30, Active, not recruiting, Sponsor: Ad scientiam
- ||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects (clinicaltrials.gov) - Jun 27, 2016
P3, N=180, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Trial initiation date, Trial primary completion date: Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Jun 25, 2016
P=N/A, N=4557, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Jan 2014 --> Jan 2000 | Trial primary completion date: May 2014 --> Dec 2012
- Trial primary completion date: Evaluation of Coagulation in Multiple Sclerosis (clinicaltrials.gov) - Jun 25, 2016
P=N/A, N=100, Recruiting, Sponsor: Bastyr University
Initiation date: Jan 2014 --> Jan 2000 | Trial primary completion date: May 2014 --> Dec 2012 Trial primary completion date: Apr 2016 --> Dec 2016
- Enrollment closed, Trial primary completion date: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). (clinicaltrials.gov) - Jun 24, 2016
P1, N=30, Active, not recruiting, Sponsor: GE Healthcare
Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion, Trial primary completion date, Adherence: ADELES: Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=131, Completed, Sponsor: Oswaldo Cruz Foundation
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Feb 2016
- New trial: Teleconsultation in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=150, Recruiting, Sponsor: Niguarda Hospital
- |||| Smyraf (peficitinib) / Astellas, Maruho
Trial completion, P2 data: A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study (clinicaltrials.gov) - Jun 23, 2016
P2, N=611, Completed, Sponsor: Astellas Pharma Global Development, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Feb 2016 Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal: A Performance Evaluation of the Enlite 3 Sensor (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=0, Withdrawn, Sponsor: Medtronic Diabetes
Active, not recruiting --> Completed N=30 --> 0 | Not yet recruiting --> Withdrawn
- Xeljanz (tofacitinib) / Pfizer
Clinical: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 23, 2016
P1, N=38, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
N=30 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- New trial: RADAR1- Trial of a New Blood Sample Method (Remote Arthritis Disease Activity MonitoR) (clinicaltrials.gov) - Jun 22, 2016
P=N/A, N=100, Not yet recruiting, Sponsor: University of Ulster
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial primary completion date: Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris (clinicaltrials.gov) - Jun 22, 2016
P3, N=1, Terminated, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> May 2022
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
New trial: Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine (clinicaltrials.gov) - Jun 22, 2016
P=N/A, N=850, Completed, Sponsor: Hoffmann-La Roche
- | Ocrevus (ocrelizumab) / Roche, Biogen
New P3 trial: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jun 21, 2016
P3, N=0, Available, Sponsor: Genentech, Inc.
- Enrollment open: High Intensity Interval Training and Rheumatoid Arthritis (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=26, Recruiting, Sponsor: Duke University
Trial primary completion date: Feb 2016 --> May 2022 Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal: The Impact of Continuous Glucose Monitoring Use on Sleep in Parents of Children With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=0, Withdrawn, Sponsor: Wolfson Medical Center
Not yet recruiting --> Recruiting N=30 --> 0 | Recruiting --> Withdrawn
- ||| mezagitamab (TAK-079) / Takeda
Trial completion: A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants (clinicaltrials.gov) - Jun 21, 2016
P1, N=82, Completed, Sponsor: Takeda
N=30 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date: CARNet : Self-Monitoring and Co-driving in Rheumatology With Internet : Rheumatoid Arthritis Cohort (Usual Care Study) (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=320, Completed, Sponsor: Association Accompagnement pour un Internet en Médecine et Santé au Service des Usagers
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- New trial: Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis (clinicaltrials.gov) - Jun 20, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: Brugmann University Hospital
- ||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 20, 2016
P2, N=159, Active, not recruiting, Sponsor: UCB Celltech
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Recruiting --> Active, not recruiting | N=102 --> 159
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial termination, Trial primary completion date: Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris (clinicaltrials.gov) - Jun 20, 2016
P3, N=1, Terminated, Sponsor: GlaxoSmithKline
Withdrawn --> Terminated | Trial primary completion date: May 2022 --> Feb 2016; Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment closed, Trial primary completion date, IO biomarker: Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (clinicaltrials.gov) - Jun 18, 2016
P1/2, N=41, Active, not recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
This decision is not linked to any safety consideration. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> May 2016
- New trial: GENEVIR: Gene-virus Interactions Implicated in Type 1 Diabetes (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=1100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Duration of Immune Response to Influenza Vaccination in Patients With RA (clinicaltrials.gov) - Jun 17, 2016
P4, N=87, Completed, Sponsor: Bassett Healthcare
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> May 2016 Active, not recruiting --> Completed
- ||| New trial: Excia T Cementless EBRA Study (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=100, Not yet recruiting, Sponsor: Aesculap AG
- ||| New trial: VEGA Prospective Kiel (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=100, Recruiting, Sponsor: Aesculap AG
- New trial, IO biomarker: Immune Profile in Subjects With New Onset Type 1 Diabetes (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
- FR104 / OSE Immunotherapeutics, Asahi Kasei
New P1 trial: Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104 (clinicaltrials.gov) - Jun 16, 2016
P1, N=64, Active, not recruiting, Sponsor: OSE Immunotherapeutics